Greenfern Industries and Ampyl Sciences are announcing the first export of Greenfern's medicinal cannabis flower under Ampyl's brand CannFX. The product is a non-irradiated premium New Zealand cultivated strain which will be made available to patients in the EU and UK.
Greenfern Industries has sold its second harvested batch to Ampyl Sciences as part of a multi-year supply agreement. This new pathway to revenue will provide consistent cashflow for the Taranaki company, which has ramped up production in its new cultivation facility.
Dan Casey, Managing Director of Greenfern Industries said: "We are excited to be contributing to patients' needs into the EU and UK markets, which are some of the largest markets globally. Our cultivation productivity has been increasing by more than 50% since commissioning the facility in August 2023 and subsequent harvests are already indicating significant volume increases."
Bastiaan Kramer, CEO of Ampyl Sciences, commented: "Following our successful 2022 launch of the first New Zealand-grown medicinal cannabis product into Germany and our 2023 launch of the first New Zealand-grown medicinal cannabis product into the UK, we are proud to now launch Greenfern's strain into these rapidly expanding markets. We are excited to continue developing our relationship with Greenfern moving forward."
For more information:
Greenfern
www.gfi.nz